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ORIGINAL RESEARCH
Abstract: Lung volume reduction surgery (LVRS) has been shown to improve lung function 
and exercise tolerance in patients with severe emphysema. Some predictors of poor outcome 
have been described but the role of alpha1-antitrypsin (α1-AT) deﬁ  ciency is still not well known. 
The aim of this study was to analyze the results of unilateral LVRS in our center according 
to the α1-AT status. The results of LVRS in 17 deﬁ  cient patients and 35 nondeﬁ  cient patients 
were analyzed at 3–6 months and 1 year after surgery. Compared with baseline, a signiﬁ  cant 
improvement of FEV1, partial pressure in arterial blood (PaO2), dyspnea score and walking 
distance was observed in the two groups at 3–6 months after surgery and the studied parameters 
remained signiﬁ  cantly improved at 1 year in the nondeﬁ  cient group. By contrast, PaO2 and walk-
ing distance returned towards baseline in the deﬁ  cient group at 1 year whereas improvement 
of FEV1 and dyspnea score was persistent. Mean values of FEV1 at baseline, 3–6 months, and 
1 year were 22 ± 6%, 29 ± 11%, and 26 ± 9% and 28 ± 12%, 38 ± 17%, and 40 ± 17% predicted in the 
deﬁ  cient group and in the non-deﬁ  cient group, respectively. In conclusion, the functional beneﬁ  t 
is short-lasting in α1-AT deﬁ  cient patients after unilateral LVRS.
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Introduction
Emphysema is a progressive, debilitating disease associated with a high rate of 
morbidity. LVRS has been shown to be effective in providing short-term, medium-term, 
and long-term beneﬁ  t in patients with emphysema (Cooper et al 1996; Flaherty and 
Martinez 2000; Yusen et al 2003; Weder 2003). The NETT study, a large, randomized, 
controlled trial comparing LVRS and medical therapy, has also shown that LVRS is 
able to provide a better 24-month functional outcome than medical treatment alone 
but without difference in mortality rate (NETT 2003). Moreover, this study was able 
to deﬁ  ne a group of patients with high risk of mortality after LVRS (NETT 2001). 
While several teams have identiﬁ  ed predictive factors of good functional results (Wang 
et al 1997; NETT 2003; Ingenito et al 1998, 2001; Thurnheer et al 1999), the inﬂ  u-
ence of α1-AT deﬁ  ciency on functional results remains debated. The studies which 
have focused on the results of LVRS in patients with α1-AT deﬁ  ciency have yielded 
controversial results (Cooper et al 1996; Cassina et al 1998; Gelb et al 1999; Rischer 
et al 1999). Taking these results into account, the ATS–ERS statement on the standards 
for the diagnosis and management of individuals with α1-AT deﬁ  ciency has recently 
concluded that LVRS offers only short-term beneﬁ  ts for most deﬁ  cient patients and 
that LVRS should not be recommended in these patients pending additional studies 
(ATS–ERS 2003).
In 1994, a prospective program of LVRS was started at our center. The α1-AT 
deﬁ  cient patients were not excluded a priori from the program thus giving us 
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an opportunity to evaluate the beneﬁ  t of LVRS in these 
patients. The aim of the present study was to analyze our 
results of LVRS in patients with α1-AT deﬁ  ciency and 
to compare these results with those obtained in patients 
without deﬁ  ciency. 
Materials and methods
Patients who met the predeﬁ  ned selection criteria (see 
below), and who accepted the risks and the uncertainties 
of LVRS underwent either bilateral or unilateral LVRS 
which were performed by the same surgeon (GL). After 
surgery, the patients were asked to visit our center at 
regular intervals in order to assess their functional results. 
Between January 1994 and December 2001, 66 patients 
underwent unilateral LVRS whereas 17 patients had 
bilateral surgery.
In order to homogenize the data, we selected only 
the patients who underwent unilateral LVRS. Among 
the 66 patients who had unilateral LVRS, 13 patients in 
whom the α1-AT status was unknown were excluded from 
this study. One patient who underwent LVRS after lung 
transplantation was also excluded. Thus, 52 patients in 
whom the α1-AT status was known form the basis of the 
study. α1-AT deﬁ  ciency was found in 17 patients (deﬁ  cient 
group) whereas 35 patients had no deﬁ  ciency (nondeﬁ  cient 
group). α1-AT deﬁ  ciency was deﬁ  ned as PiZZ phenotype 
or α1-AT serum level below 50 mg/ml. The ﬁ  les of these 
patients were analyzed and several items were retrieved: 
preoperative characteristics, perioperative and overall 
mortality, post-operative morbidity. The functional results 
of LVRS in the two groups were studied at 3–6 months 
and at 1 year after surgery.
Selection criteria
To be considered for LVRS, the patients had to meet the 
following selection criteria: physiologic evidence of severe 
airﬂ  ow obstruction (FEV1 < 40% predicted), hyperinﬂ  ation 
(deﬁ  ned as a TLC value above predicted without threshold 
of TLC), severe dyspnea deﬁ  ned as a Fletcher dyspnea score 
> 2, and CT scan evidence of advanced emphysema with some 
degree of heterogeneity in the distribution of emphysema.
The exclusion criteria for LVRS were as follows: age 
> 75 years, presence of giant bulla deﬁ  ned as a bulla > 1/3 
of hemithorax on the CT scan, severe left ventricular dys-
function, or BMI < 18 kg.m
–2. The levels of hypercapnia and 
pulmonary hypertension were not considered as exclusion 
criteria.
Pre- and post-operative evaluation
All patients underwent baseline pulmonary function tests, 
CT scan of the thorax, and lung ventilation–perfusion scan. 
Cardiac function evaluation was made using echocar-
diography and right heart catheterization. Coronary 
angiography was performed in case of symptoms. Pulmo-
nary function tests included spirometry, and measurement 
of DLCO and thoracic gas volumes. TLC was measured 
by standardized body plethysmography (MedGraphics 
1085 series Plethysmograph). Exercise capacity was 
assessed by the 6MWD test. Arterial blood gas analysis 
was made at rest on room air (AVL analyser, Radiometer, 
Copenhagen). Severity of pre- and post-operative dysp-
nea was assessed using the score described by Fletcher 
(1952). Pulmonary artery pressure and cardiac index were 
evaluated during right heart catheterization. Pre-operative 
CT and ventilation–perfusion scans were used to identify 
target areas for lung resection. Post-operatively, all these 
tests were repeated between 3 and 6 months and at 1 year 
except for right heart catheterization which was not 
performed after surgery.
Surgical procedure
All patients underwent unilateral LVRS at the same center, 
by the same thoracic surgeon (GL). The LVRS procedure 
was performed in all cases via unilateral thoracotomy. The 
worst areas of emphysematous lung were resected by stapling 
guided by the results of CT and lung perfusion scan.
Statistical analysis
Baseline characteristics are reported as mean and stand-
ard deviation. Preoperative and post-operative differences 
between groups were compared by means of Student’s t-test. 
In each group, comparisons between baseline values and 
values at 3–6 months and between baseline values and values 
at 1 year were made using paired Student’s t-test. The com-
parison of the relative gain of FEV1 at 3–6 months and 1 year 
from baseline between the two groups was analyzed using 
t-test (the variables are normally distributed). The proportion 
of patients with improved FEV1 (deﬁ  ned as a gain > 150 ml) 
and 6MWD (deﬁ  ned as a gain > 50 m) at 3–6 months and 1 
year was assessed by a χ2 test. A p value <  0.05 was consid-
ered statistically signiﬁ  cant.
Results
Baseline characteristics of the patients are shown in Table 
1. All patients were dyspneic at rest or for mild exercise International Journal of COPD 2006:1(2) 203
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lower lobe in all the α1-AT deﬁ  cient patients and on the 
lower or the upper lobes in the nondeﬁ  cient group. Among 
the 35 patients in the latter group, 19 had predominant lower 
lobe lesions.
Mortality and morbidity
Hospital mortality was deﬁ  ned as death occurring before a 
patient’s discharge from the hospital after LVRS. Two patients 
died within this period, resulting in a mortality rate of 3.8%. 
These patients from the nondeﬁ  cient group died at day 16 from 
septic shock related to peritonitis and at day 36 from bacte-
rial pneumonia. Neither patients with PaCO2 level > 55 mmHg 
or pulmonary artery hypertension > 55 mmHg died during 
hospital stay. If we except the patients who died in the early 
post-operative period, the remaining 50 patients were alive at 
3–6 months and at 1 year. Thus, the 1-year mortality rate among 
the followed patients was 3.8%.
LVRS morbidity consisted of lower respiratory tract 
infection and persistent air leak. No other complication was 
observed in our series. The average duration of chest drainage 
was 9.0 ± 5 days and 9.8 ± 6 days in the nondeﬁ  cient group 
and in the deﬁ  cient group, respectively. The average duration 
of hospital stay was 24 days in the two groups.
Concerning lower respiratory tract infection, 3 of the 
17 patients in the deﬁ  cient group and 4 of the 35 patients 
in the nondeﬁ  cient group developed nosocomial purulent 
bronchitis or pneumonia.
Functional results
At 3–6 months, functional data were available in all patients 
(except in the two who died early in the nondeﬁ  cient group) 
while the data were lacking at 1 year in 8 other patients (1 in 
the deﬁ  cient group and 7 in the nondeﬁ  cient group). While 
1 of these 8 patients with nonavailable functional results 
at 1 year was reoperated on the controlateral side between 
6 months and 1 year, the other 7 patients did not undergo their 
1-year evaluation. The functional results in the two groups 
are shown in Table 2 and in Figures 1, 2, and 3. 
Deﬁ  cient group
Compared with baseline, a signiﬁ  cant improvement of mean 
FEV1 at 3–6 months was observed in the α1-AT deﬁ  cient 
group (from 22.2 ± 6% pred to 28.9 ± 11% pred; p < 0.002). 
A signiﬁ  cant gain in PaO2 and 6MWD and a signiﬁ  cant 
decrease in dyspnea score were also observed. At 1 year post-
operative, a decline in pulmonary function values, 6MWD, and 
PaO2 was noted but FEV1 value and dyspnea score remained 
signiﬁ  cantly improved compared with baseline. 
Table 1 Baseline characteristics of patients with α1-AT 
deﬁ  ciency and without deﬁ  ciency
Value  α1-AT   Nondeﬁ  cient   p
 deﬁ  cient   group
 group  n=35
 n=17 
Age (years)  56 ± 9a  54 ± 11 0.62
BMI (m2/kg) 20 ± 4 22 ± 4 0.07
Smoking habit (pack-years)  18.4 ± 14 41.1 ± 27 0.007
FEV1 (% pred)  22.2 ± 5.7 28 ± 11.9 0.06
FEV1 (ml)  613 ± 163 907 ± 453 0.013
FEV1 post-BD (% pred)  24 ± 6.7 29.9 ± 13 0.09
FVC (% pred)  48 ± 11 50 ± 17 0.65
RV (% pred)  278 ± 48 259 ± 71 0.34
FRC (% pred)  201 ± 35 182 ± 34 0.06
TLC (% pred)  138 ± 18 129 ± 21 0.15
IC (% pred)  62 ± 19 67 ± 18 0.37
6MWD (m)  237 ± 145 340 ± 173 0.039
Fletcher score  4.18 ± 0.73 3.57 ± 0.85 0.015
PaO2 (mmHg)  62 ± 9.7 67.6 ± 10.8 0.07
PaCO2 (mmHg)  40 ± 6.71 40.7 ± 6.1 0.7
PAP systolic (mmHg)  37 ± 7.3 36 ± 7.7 0.55
aValues are expressed as mean ± standard deviation.
Abbreviations: BD, bronchodilator; pred, predicted.
(Fletcher dyspnea score = 4.2 ± 0.7 in the deﬁ  cient group and 
3.6 ± 0.8 in the nondeﬁ  cient group; p = 0.02). We observed 
a severe limitation in exercise capacity in the two groups 
(6MWD = 237 ± 145 m and 340 ± 173 m in the deﬁ  cient group 
and in the nondeﬁ  cient groups, respectively; p = 0.04).
The deﬁ  cient patients tended to have more severe airﬂ  ow 
obstruction than nondeﬁ  cient patients (FEV1= 22.2 ± 6% pre-
dicted [pred] and 28 ± 12% pred in the deﬁ  cient group and in 
the nondeﬁ  cient group, respectively; p = 0.06). Severe hyper-
inﬂ  ation was observed in the two groups (TLC = 138 ± 18% 
pred and RV = 278 ± 48% pred in the deficient group, 
TLC = 129 ± 21% pred and RV = 259 ± 71% pred in the nonde-
ﬁ  cient group; p = 0.15 and p = 0.34, respectively). Mean PaO2 
was 62 ± 10 mmHg in the deﬁ  cient group and 68 ± 11 mmHg 
in the nondeﬁ  cient group (p = 0.07)
One patient in the nondeﬁ  cient group and 1 patient in the 
deﬁ  cient group had severe hypercapnia deﬁ  ned by a PaCO2 
level of more than 55 mmHg. Severe pulmonary hyperten-
sion (systolic pulmonary artery pressure > 55 mmHg) was 
observed in 1 patient with α1-AT deﬁ  ciency and in none of the 
patients without deﬁ  ciency. Sixteen patients in the deﬁ  cient 
group and 12 patients in the nondeﬁ  cient group had oxygen 
supplementation at rest. Out of the 17 patients with α1-AT 
deﬁ  ciency, the PI phenotype was available in 15. All of them 
had PIZZ phenotype.
Upon CT scan examination, all patients had heterogene-
ously distributed emphysema, which predominated on the International journal of COPD 2006:1(2)
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Nondeﬁ  cient group
In the nondeﬁ  cient group, RV, TLC, FRC, FEV1, 6MWD, 
dyspnea score, and PaO2 values improved signiﬁ  cantly at 
3–6 months compared with baseline, the gain being persist-
ent at 1 year.
Comparison between the two groups
At 3–6 months, the FEV1 values were not signiﬁ  cantly dif-
ferent but a statistical difference was observed at 1 year 
(26 ± 9% and 40 ± 17% pred, in the deﬁ  cient group and the 
nondeﬁ  cient group respectively; p < 0.005). Compared with 
pre-operative mean value, the relative gain in FEV1 at 3–6 
months was 29 ± 26% and 34 ± 36% pred in the deﬁ  cient and 
in the nondeﬁ  cient group, respectively (p = NS). The relative 
gain in FEV1 at 1 year compared with baseline tended to be 
higher in the nondeﬁ  cient group than in the deﬁ  cient group 
(34 ± 35% and 16 ± 24%, respectively, without reaching sta-
tistical signiﬁ  cance; p = 0.07).
The proportion of patients with improvement in FEV1 
and 6MWD in the two groups is given in Table 3. Although 
no statistical signiﬁ  cance was achieved, the percentage of 
patients improved at 1 year tended to be higher in the non-
deﬁ  cient group.
Table 2 Follow-up data after LVRS in the α1-AT deﬁ  cient and nondeﬁ  cient groups
Group   FEV1  RV TLC FRC  6MWD  dyspnea    PaO2  PaCO2
    (% pred)  (% pred)  (% pred)  (% pred)  (m)  score  (mmHg)  (mmHg)
α1-AT deﬁ  ciency  pre-op (n = 17) 22.2 ± 5.7a  278 ± 48 138 ± 18 201 ± 35 237 ± 145 4.18 ± 0.73 62 ± 9.7 40 ± 6.71
  3–6 months (n = 17) 28.9 ± 11.2* 248 ± 57 132 ± 16 191 ± 28 310 ± 154* 3.1 ± 0.9* 67 ± 6.8* 38 ± 4.4
  12 months (n = 16) 25.9 ± 9.1* 259 ± 13.5 133 ± 20 200 ± 32 270 ± 151 3.2 ± 0.6* 65.2 ± 8.2 38.6 ± 4
nondeﬁ  cient  pre-op (n = 35) 28 ± 11.9 259 ± 71 129 ± 21 182 ± 34 340 ± 173 3.57 ± 0.85 67.6 ± 10.8 40.7 ± 6.1
group  3–6 months (n = 33) 36.6 ± 16.8* 217 ± 71* 119 ± 20* 166 ± 37* 408 ± 163* 2.7 ± 1.2* 72.3 ± 12.4* 40.2 ± 6.1
  12 months (n = 26)  39.7 ± 17.2*  209 ± 63*  119 ± 18*  161 ± 32*  421 ± 153*  2.6 ± 1.2*  71.8 ± 9.3*  38.5 ± 3.5
*Signiﬁ  cantly different from baseline value.
aValues are expressed as mean ± standard deviation.
Abbreviations: pred, predicted; pre-op, pre-operatively.
Nondeficient group
Deficient group
45
40
42.5
35
30
37.5
27.5
22.5
25
20
32.5
Pre-op 3-6 months 1 year
*
*
*
*
F
E
V
1
 
(
%
 
p
r
e
d
)
Figure 1 Evolution of FEV1 before LVRS, at 3–6 months, and at 1 year after LVRS.
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Figure 3 Evolution of 6MWD before LVRS, at 3–6 months, and at 1 year after 
LVRS.
*p < 0.05 compared with pre-operative values.
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Figure 2 Evolution of dyspnea score before LVRS, at 3–6 months, and at 1 year 
after LVRS.
*p < 0.05 compared with pre-operative values.
Table 3 Number of patients with persistent increase in FEV1 
and 6MWD according to α1-AT deﬁ  ciency status (gain ex-
pressed in comparison with baseline)
Parameters  Group  at 6 months  at 12 months
  n %  n  %
gain in FEV1 
> 150 ml nondeﬁ   cient  13/33  39.4 9/26  34.6
 deﬁ   cient  4/17  23.5  3/16  18.7
gain in 6MWD 
> 50 m nondeﬁ   cient  21/33  63.6  15/26  57.7
 deﬁ   cient  12/17  70.6  6/17  35.3International Journal of COPD 2006:1(2) 205
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of emphysema, since better functional results have been 
observed after upper lobe surgery (Cooper et al 1996; 
McKenna et al 1997; Ingenito et al 1998; Coxson et al 
2003; NETT 2003). As a matter of fact, the predominant 
site of destruction was in the lower lobes in all of our 
patients but only in 10/21 patients in the study by Tutic 
et al (2004). Another ﬁ  nding of our study was the differ-
ence found in α1-AT deﬁ  cient patients between objective 
improvement (lung volume measurements, 6MWD, PaO2) 
and subjective beneﬁ  t (dyspnea score) which persisted for 
1 year. Such a difference had been previously reported in 
nondeﬁ  cient patients (Gelb et al 1998, 2001; Flaherty et al 
2001) and was also found by Tutic et al (2004).
By contrast with previous studies, our study analyzed the 
results of unilateral LVRS in deﬁ  cient patients. Our surgi-
cal approach (unilateral thoracotomy) could not explain the 
poorer results of LVRS in α1-AT deﬁ  cient patients. Indeed, 
the nondeﬁ  cient patients had the same surgical approach, 
giving results in accordance with those previously reported 
after unilateral LVRS (relative gain in FEV1 of 20%–30% 
in most studies) (Flaherty and Martinez 2000). α1-AT de-
ﬁ  cient patients are known to have emphysematous lesions 
which predominate on lower lobes, and, as said previously, 
poorer 6-month results have been observed when LVRS is 
performed on lower lobes rather than on upper lobes (Cooper 
et al 1996; McKenna et al 1997; NETT 2003; Ingenito et al 
1998; Coxson et al 2003). Thus, a question arises: are the 
functional results in deﬁ  cient patients related to the location 
of emphysematous lesions or to the α1-AT deﬁ  ciency per se? 
In our series, all deﬁ  cient patients had predominant lower-
lobe lesions whereas one third of nondeﬁ  cient patients had 
predominant lower-lobe lesions. The results of LVRS in our 
nondeﬁ  cient patients with predominant lower-lobe lesions 
showed that, as was the case in deﬁ  cient patients, FEV1 
returned to baseline at 1 year (data not shown). Therefore, 
we hypothesize that the poorer functional results in deﬁ  cient 
patients might be related to nonapical emphysema surgery 
rather than to α1-AT deﬁ  ciency.
Whether α1-AT deﬁ  cient patients who present with severe 
emphysema are suitable for LVRS or for lung transplanta-
tion remains open to debate. The functional results of lung 
transplantation are clearly superior to what is provided by 
LVRS (Gelb et al 1998) but the risks of the procedure are 
much higher for lung transplantation. The current policy at 
our center is to explain the potential risks and beneﬁ  ts of 
both procedures in patients with emphysema and to favour 
LVRS when the selection criteria are met. In the particular 
case of α1-AT deﬁ  cient patients, given our results, we tend to 
Discussion
α1-AT deﬁ  ciency is an hereditary disorder characterized by 
low serum levels of α1-AT and increased risk of emphysema 
at an early age. Augmentation therapy by regular intravenous 
infusion of α1-AT has been shown to increase the serum level 
of this protein and is recommended for the management of 
α1-AT deﬁ  cient patients, particularly in individuals with 
moderate airﬂ  ow obstruction (ATS–ERS 2003). A clinical 
efﬁ  cacy in terms of survival or pulmonary function has been 
suggested but has never been convincingly demonstrated 
(Seersholm et al 1997; AADR 1998; Wencker et al 2001). 
Besides augmentation therapy, 2 surgical procedures may 
be considered in case of advanced emphysema: lung trans-
plantation and LVRS.
In their study describing the results of 150 patients who 
underwent LVRS, Cooper et al (1996) stated that the beneﬁ  t 
was less important in patients with lower lobe lesions or α1-
AT deﬁ  ciency. The functional results of LVRS in deﬁ  cient 
patients have been previously analyzed in a more speciﬁ  c 
way by several authors (Cassina et al 1998; Gelb et al 1999; 
Ritscher et al 1999). Cassina et al (1998) noted a transient 
functional improvement in patients with α1-AT deﬁ  ciency 
with return to baseline 6–12 months after surgery except for 
6MWD. In contrast, Gelb et al (1999), reporting the results 
of LVRS in 6 α1-AT deﬁ  cient patients, observed a modest 
improvement in some functional parameters lasting more 
than 22 months post-operative in 4 cases. Similarly, no im-
portant differences were observed 18 months after surgery 
between 8 α1-AT deﬁ  cient patients and 46 patients without 
deﬁ  ciency (Ritscher et al 1999). Recently, Tutic et al (2004) 
reported results of LVRS in 21 α1-AT deﬁ  cient patients. A 
functional beneﬁ  t in terms of FEV1 persisted up to 1 year 
after surgery but the gain of LVRS was smaller and shorter 
lasting than in patients with pure smoker’s emphysema. In 
the above-mentioned studies, baseline status of the patients 
was similar to that of our patients, but the surgical approach 
was always bilateral.
The results of the present study show that the effects 
of LVRS in α1-AT deﬁ  cient patients are short lasting since 
most functional parameters returned towards baseline at 
1 year after surgery. The magnitude of the gain in FEV1, 
walking distance, and dyspnea score in the deﬁ  cient group 
was not lower than in nondeﬁ  cient patients but the dura-
tion of improvement was shorter. Thus, our results are in 
accordance with those of Cassina et al (1998) but are not 
in opposition to those of Tutic et al (2004). In the latter 
study, the duration of improvement was somewhat longer 
but the difference might be explained by the distribution International journal of COPD 2006:1(2)
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favour lung transplantation but the LVRS remains an option 
even though the duration of beneﬁ  t is probably shorter than 
in nondeﬁ  cient patients.
In summary, our experience suggests that the functional 
beneﬁ  t is short lasting in α1-AT deﬁ  cient patients who un-
dergo unilateral LVRS for emphysema. Based on these 
results, we consider that LVRS remains an option but that 
lung transplantation, if possible, is more appropriate for most 
of these patients.
Abbreviations
α1-AT, alpha1-antitrypsin; BMI, body mass index; FEV1, forced expira-
tory volume in one second; FRC, functional residual capacity; FVC, 
forced vital capacity; IC, inspiratory capacity; LVRS, lung volume re-
duction surgery; PaO2, partial pressure in arterial blood; PAP, pulmonary 
artery pressure; RV, residual volume; TLC, total lung capacity; 6MWD, 
6 minute walking distance; DLCO, diffusing capacity of the lungs for 
carbon monoxide.
References
[AADR] The alpha-1-Antitrypsin deﬁ  ciency registry study group. 1998. 
Survival and FEV1 decline in individuals with severe deﬁ  ciency of 
alpha1-antitrypsin. Am J Respir Crit Care Med, 158:49–59.
[ATR–ERS] American Thoracic Society/European Thoracic Society 
statement: standards for diagnossi and management of individuals 
with α1-Antitrypsin deﬁ  ciency. 2003. Am J Respir Crit Care Med, 
168:818–900.
Cassina PC, Teschler H, Konietzko N, et al. 1998. Two-year results after lung 
volume reduction surgery in α1-antitrypsin deﬁ  ciency versus smoker’s 
emphysema. Eur Respir J, 12:1028–1032.
Cooper JD, Patterson G, Sunderesan RS, et al. 1996. Results of 150 consecu-
tive bilateral lung volume reduction procedures in patients with severe 
emphysema. J Thorac Cardiovasc Surg, 112:1319–30.
Coxson HO, Whittall KP, Nakano Y, et al. 2003. Selection of patients for 
lung volume reduction surgery using a law analysis of the computed 
tomographic scan. Thorax, 58:510–14.
Flaherty KR, Martinez FJ. 2000. Lung volume reduction surgery for em-
physema. Clin Chest Med, 21:819–48.
Flaherty KR, Kazerooni EA, Curtis JL, et al. 2001. Short term and long 
term outcomes after bilateral lung volume reduction surgery. Chest, 
119:1337–46.
Fletcher CM. 1952. The clinical diagnosis of pulmonary emphysema: an 
experimental study. Proc R Soc Med, 45:577–84.
Gaissert HA, Trulock EP, Cooper JD, et al. 1996. Comparison of early functional 
results after volume reduction or lung transplantation for chronic obstructive 
pulmonary disease. J Thorac Cardiovasc Surg, 111:296–306.
Gelb AF, Brenner M, McKenna RJ, et al. 1998. Serial lung function and 
elastic recoil 2 years after lung volume reduction surgery for emphy-
sema. Chest, 113:1497–506.
Gelb AF, McKenna RJ, Brenner M, et al. 1999. Lung function after bilateral 
lower lung volume reduction surgery for α1-antitrypsin emphysema. 
Eur Respir J, 14:928–33.
Gelb AF, McKenna RJ, Brenner M, et al. 2001. Lung function 5 years after 
lung volume reduction surgery for emphysema. Am J Respir Crit Care 
Med, 163:1562–6.
Ingenito EP, Evans RB, Loring SH, et al. 1998. Relation between preoperative 
inspiratory lung resistance and the outcome of lung volume reduction 
surgery for emphysema. N Engl J Med, 338:1181–5.
Ingenito EP, Loring SH, Moy ML, et al. 2001. Comparison of physiologi-
cal and radiological screening for lung volume reduction surgery. Am 
J Respir Crit Care Med, 163:1068–73.
McKenna RJ, Brenner M, Fischel RJ, et al. 1997. Patient selection cri-
teria for lung volume reduction surgery. J Thorac Cardiovasc Surg, 
114:957–67.
[NETT] National emphysema treatment trial research group. 2001. Patients 
at high risk of death after lung volume reduction surgery. N Engl J 
Med, 345:1075–83.
[NETT] National emphysema treatment trial group. 2003. A randomised 
trial comparing lung-volume-reduction surgery with medical therapy 
for severe emphysema. N Engl J Med, 348:2059–73.
Ritscher D, Hamacher J, Weder W, et al. 1999. Lung volume reduction 
surgery in patients with a1-antitrypsin deﬁ  ciency and emphysema. Eur 
Respir J, 14:S275.
Seersholm N, Wencker M, Banik N, et al. 1997. Does alpha1-antitrypsin 
augmentation therapy slow the annual decline in FEV1 in patients 
with severe hereditary alpha1-antitrypsin deﬁ  ciency? Eur Respir J, 
10:2260–3.
Thurnheer R, Engel H, Weder W, et al. 1999. Role of lung perfusion scintig-
raphy in relation to chest computed tomography and pulmonary function 
in the evaluation of candidates for lung volume reduction surgery. Am 
J Respir Crit Care Med, 159:301–10.
Tutic M, Bloch KE, Lardinois D, et al. 2004. Long term results after lung 
volume reduction surgery in patienbts with α1-antitrypsin deﬁ  ciency. 
J Thorac Cardiovasc Surg, 128:408–13.
Wang SC, Fischer KC, Slone RM, et al. 1997. Perfusion scintigraphy in the 
evaluation for lung volume reduction surgery: correlation with clinical 
outcome. Radiology, 205:243–8.
Wencker M, Fuhrmann B, Banik N, et al. 2001. Longitudinal follow-up of 
patient with α1-Protease inhibitor deﬁ  ciency before and during therapy 
with IV α1-Protease inhibitor. Chest, 119:737–44.
Weder W. 2003. Lung volume reduction surgery. Eur Resp Mon, 26:40–6.
Yusen R D, Lefrak SS, Gierada DS, et al. 2003. A prospective evaluation 
of lung volume reduction surgery in 200 consecutive patients. Chest, 
123:1026–37.